Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

Alfred H. Schinkel(Oncode Institute), Piet Borst(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Liesbeth van Deemter(The Netherlands Cancer Institute), Willem E. Fibbe(Leiden University Medical Center), Els Wagenaar(The Netherlands Cancer Institute), Martin A. van der Valk(The Netherlands Cancer Institute), Arie C. Voordouw(The Netherlands Cancer Institute), Hergen Spits(Erasmus MC Cancer Institute), Ulrich Mayer(The Netherlands Cancer Institute), Carla A.A.M. Mol(The Netherlands Cancer Institute), Jaap J. M. Smit(The Netherlands Cancer Institute), J. M. J. M. Zijlmans(Leiden University)
Proceedings of the National Academy of Sciences
April 15, 1997
10.1073/pnas.94.8.4028
Cited by 941

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Immunomodulatory properties of mesenchymal stromal cells
|Blood|2007|1.8k
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
|Science|2013|1.2k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k